You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 24, 2025

Sandoz Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Sandoz

Drugs and US Patents for Sandoz

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz MEROPENEM meropenem INJECTABLE;INJECTION 091201-002 Mar 29, 2011 DISCN No No ⤷  Try for Free ⤷  Try for Free
Sandoz TACROLIMUS tacrolimus CAPSULE;ORAL 065461-003 Aug 10, 2009 AB RX No No ⤷  Try for Free ⤷  Try for Free
Sandoz BREXPIPRAZOLE brexpiprazole TABLET;ORAL 213570-002 Sep 26, 2022 DISCN No No ⤷  Try for Free ⤷  Try for Free
Sandoz ZOFRAN ondansetron hydrochloride INJECTABLE;INJECTION 020007-001 Jan 4, 1991 DISCN Yes No ⤷  Try for Free ⤷  Try for Free
Sandoz ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE ondansetron hydrochloride INJECTABLE;INJECTION 077551-001 Jun 27, 2007 AP RX No No ⤷  Try for Free ⤷  Try for Free
Sandoz TIMOLOL MALEATE timolol maleate SOLUTION, GEL FORMING/DROPS;OPHTHALMIC 020963-002 Oct 21, 1998 AB RX Yes Yes ⤷  Try for Free ⤷  Try for Free
Sandoz THIORIDAZINE HYDROCHLORIDE thioridazine hydrochloride CONCENTRATE;ORAL 088308-001 Nov 23, 1983 DISCN No No ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Sandoz

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sandoz FOCALIN XR dexmethylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021802-006 Aug 11, 2010 6,635,284 ⤷  Try for Free
Sandoz ZOFRAN ondansetron hydrochloride TABLET;ORAL 020103-003 Aug 27, 1999 4,695,578*PED ⤷  Try for Free
Sandoz VIVELLE estradiol SYSTEM;TRANSDERMAL 020323-002 Oct 28, 1994 4,994,278 ⤷  Try for Free
Sandoz VIVELLE-DOT estradiol SYSTEM;TRANSDERMAL 020538-005 Jan 8, 1999 6,024,976 ⤷  Try for Free
Sandoz AZOPT brinzolamide SUSPENSION/DROPS;OPHTHALMIC 020816-001 Apr 1, 1998 5,378,703*PED ⤷  Try for Free
Sandoz AZOPT brinzolamide SUSPENSION/DROPS;OPHTHALMIC 020816-001 Apr 1, 1998 5,461,081*PED ⤷  Try for Free
Sandoz VIVELLE estradiol SYSTEM;TRANSDERMAL 020323-005 Aug 16, 2000 4,994,278 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for SANDOZ drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 2004-07-27
➤ Subscribe Extended-release Capsules 20 mg, 30 mg and 40 mg ➤ Subscribe 2006-08-21
➤ Subscribe Capsules 5 mg/40 mg and 10 mg/40 mg ➤ Subscribe 2006-11-17
➤ Subscribe Capsules 1.5 mg, 3 mg, 4.5 mg and 6 mg ➤ Subscribe 2004-04-21
➤ Subscribe Transdermal System Extended-release 13.3 mg/24 hr ➤ Subscribe 2013-01-22
➤ Subscribe Injection 1 mg/mL, 50 mL vials ➤ Subscribe 2011-12-16
➤ Subscribe Extended-release Capsules 15 mg ➤ Subscribe 2007-05-14
➤ Subscribe For Injection 250 mg/vial ➤ Subscribe 2009-09-01
➤ Subscribe Extended-release Capsule 30 mg ➤ Subscribe 2010-12-15
➤ Subscribe Ophthalmic Solution 0.00% ➤ Subscribe 2009-02-19
➤ Subscribe Extended-release capsules 25 mg ➤ Subscribe 2011-09-30
➤ Subscribe Extended-release Tablets 80 mg ➤ Subscribe 2007-03-15
➤ Subscribe Extended-release Capsules 10 mg ➤ Subscribe 2007-05-21
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 2004-05-27
➤ Subscribe Capsules 2.5 mg/10 mg, 5 mg/10 mg, 5 mg/20 mg and 10 mg/20 mg ➤ Subscribe 2004-06-09
➤ Subscribe Ophthalmic Emulsion 0.05% ➤ Subscribe 2014-05-01
➤ Subscribe Oral Solution 2 mg/mL ➤ Subscribe 2004-11-05
➤ Subscribe Injection 100 mg/mL, 2.5 mL vials ➤ Subscribe 2007-09-24
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
➤ Subscribe Oral Solution 4 mg/5 mL ➤ Subscribe 2004-12-20
➤ Subscribe Extended-release Capsules 5mg, 10mg and 20 mg ➤ Subscribe 2007-03-30
➤ Subscribe Injection 0.05 mg/mL, 100 mL vial ➤ Subscribe 2008-08-29
➤ Subscribe Extended-release Capsule 40 mg ➤ Subscribe 2010-12-20
➤ Subscribe Otic Suspension 0.3%/0.1% ➤ Subscribe 2012-07-31
➤ Subscribe Extended-release capsules 35 mg ➤ Subscribe 2011-09-29

Supplementary Protection Certificates for Sandoz Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0720599 C300688 Netherlands ⤷  Try for Free PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ROSUVASTATINE; NAT. REGISTRATION NO/DATE: RVG114002-004RVG 114008-010 2014110811; FIRST REGISTRATION: 13-9663 - 9665 20140724
1412357 77 5006-2008 Slovakia ⤷  Try for Free PRODUCT NAME: SITAGLIPTIN A METFORMIN; NAT. REG.NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REG.:CH 58450 01-03 20080408
1453521 C 2015 029 Romania ⤷  Try for Free PRODUCT NAME: LEVONORGESTREL SI ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: RO 7793/2015/001; DATE OF NATIONAL AUTHORISATION: 20150612; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): SK. 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150129
0296560 SPC/GB97/023 United Kingdom ⤷  Try for Free PRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214
2236132 CA 2015 00004 Denmark ⤷  Try for Free PRODUCT NAME: ZOLPIDEM OG FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER ZOLPIDEMTARTRAT; NAT. REG. NO/DATE: 47607 OG 47608 20120719; FIRST REG. NO/DATE: (B BE424286 OG BE424295 20120718
0984957 PA2011005,C0984957 Lithuania ⤷  Try for Free PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
1110543 08C0004 France ⤷  Try for Free PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Sandoz – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, Sandoz has emerged as a formidable player, carving out a significant niche in the generics and biosimilars market. As we delve into the competitive landscape of this pharmaceutical giant, we'll explore its market position, strengths, and strategic insights that have propelled it to the forefront of the industry.

Sandoz: A Global Pharmaceutical Powerhouse

Sandoz, a subsidiary of Novartis until its recent spin-off, has established itself as a leading force in the pharmaceutical sector. With a presence in over 160 countries, Sandoz has built a robust global network that allows it to reach diverse markets and cater to a wide range of healthcare needs.

The Sandoz Footprint

Sandoz's global reach is nothing short of impressive. Operating in more than 160 countries, the company has strategically positioned itself to serve both developed and emerging markets. This extensive geographical coverage not only enhances its market presence but also provides a buffer against regional economic fluctuations.

A Diverse Product Portfolio

At the heart of Sandoz's success lies its diverse product portfolio. The company offers a wide range of generic pharmaceutical products across various therapeutic areas, including:

  • Cardiovascular
  • Anti-infectives
  • Respiratory
  • Oncology
  • Central nervous system
  • Pain management

This diverse portfolio allows Sandoz to cater to a broad spectrum of medical needs, enhancing its market resilience and growth potential.

Market Position: A Leader in Generics and Biosimilars

Sandoz has solidified its position as a leader in the generics and biosimilars market. The company's commitment to providing high-quality, affordable healthcare solutions has resonated with healthcare providers, patients, and payers alike.

"Sandoz distributes products to wholesalers, pharmacies, hospitals, and other healthcare outlets. Sandoz is headquartered in Princeton, New Jersey, the US."[1]

The Generics Giant

In the generics market, Sandoz has established itself as a trusted name. The company's ability to produce high-quality generic medications at competitive prices has made it a preferred choice for healthcare systems looking to manage costs without compromising on quality.

Pioneering Biosimilars

Sandoz has also made significant strides in the biosimilars market. As one of the first companies to receive approval for a biosimilar in the United States, Sandoz has positioned itself at the forefront of this rapidly growing segment of the pharmaceutical industry.

Strengths That Set Sandoz Apart

Sandoz's success in the competitive pharmaceutical landscape can be attributed to several key strengths:

1. Strong Research and Development Capabilities

Sandoz invests heavily in research and development, focusing on both generics and biosimilars. This commitment to innovation allows the company to stay ahead of the curve and bring new products to market efficiently.

2. Robust Manufacturing Network

With over 30 manufacturing sites globally, Sandoz has built a robust and flexible manufacturing network. This allows the company to ensure a reliable supply of products and respond quickly to market demands.

3. Quality Assurance

Sandoz places a strong emphasis on quality, adhering to stringent regulatory standards. The company's commitment to quality has earned it a reputation for reliability among healthcare providers and patients.

4. Strategic Partnerships

Sandoz has forged strategic partnerships with other pharmaceutical companies, research institutions, and healthcare organizations. These collaborations enhance its product development capabilities and market reach.

5. Cost-Effective Production

Leveraging its global manufacturing network and economies of scale, Sandoz can produce medications cost-effectively. This allows the company to offer competitive pricing while maintaining profitability.

Strategic Insights: Navigating the Competitive Landscape

To maintain its competitive edge in the pharmaceutical industry, Sandoz has adopted several key strategies:

Focus on High-Value Generics and Biosimilars

Sandoz is strategically focusing on high-value generics and biosimilars. These products offer higher margins and face less competition compared to traditional generics.

Expansion into Emerging Markets

Recognizing the growth potential in emerging markets, Sandoz is actively expanding its presence in these regions. This strategy allows the company to tap into new revenue streams and diversify its market risk.

Digital Transformation

Sandoz is embracing digital technologies to streamline its operations, enhance customer engagement, and drive innovation. This digital transformation is crucial for staying competitive in an increasingly technology-driven industry.

Sustainability Initiatives

Recognizing the growing importance of sustainability in the pharmaceutical industry, Sandoz is implementing various sustainability initiatives. These efforts not only contribute to environmental protection but also enhance the company's reputation and appeal to environmentally conscious stakeholders.

Competitive Advantages of Sandoz

Sandoz's competitive advantages stem from its unique positioning in the pharmaceutical market:

1. Global Presence

Sandoz's extensive global footprint allows it to leverage economies of scale and tap into diverse markets.

2. Diverse Product Portfolio

The company's wide range of products across various therapeutic areas provides a buffer against market fluctuations in specific segments.

3. Strong Brand Recognition

As a subsidiary of Novartis (until its recent spin-off), Sandoz benefits from strong brand recognition and association with quality.

4. Expertise in Complex Generics and Biosimilars

Sandoz's expertise in developing and manufacturing complex generics and biosimilars sets it apart from many competitors.

5. Vertical Integration

The company's vertically integrated structure, from research and development to manufacturing and distribution, provides greater control over the value chain.

Challenges and Opportunities in the Competitive Landscape

While Sandoz enjoys a strong market position, it also faces several challenges and opportunities in the competitive pharmaceutical landscape:

Challenges

  1. Pricing Pressures: Increasing competition and government efforts to reduce healthcare costs are putting pressure on drug prices.

  2. Regulatory Hurdles: Stringent and evolving regulatory requirements pose ongoing challenges for product development and approval.

  3. Patent Cliffs: As patents for blockbuster drugs expire, Sandoz faces increased competition in the generics market.

Opportunities

  1. Growing Demand for Biosimilars: The increasing acceptance of biosimilars presents a significant growth opportunity for Sandoz.

  2. Emerging Markets: Expanding healthcare access in emerging markets offers potential for market expansion.

  3. Technological Advancements: Advances in manufacturing and drug delivery technologies could lead to more efficient production and improved products.

Future Outlook: Sandoz's Path Forward

As Sandoz navigates the competitive pharmaceutical landscape, several factors will shape its future:

1. Continued Focus on Innovation

Sandoz is likely to maintain its strong focus on research and development, particularly in complex generics and biosimilars.

2. Strategic Acquisitions and Partnerships

To enhance its product portfolio and market reach, Sandoz may pursue strategic acquisitions and partnerships.

3. Digital Health Initiatives

Embracing digital health technologies could open new avenues for patient engagement and product development.

4. Sustainability Efforts

Continued focus on sustainability could enhance Sandoz's brand image and appeal to environmentally conscious stakeholders.

Key Takeaways

  • Sandoz has established a strong global presence in the generics and biosimilars market.
  • The company's diverse product portfolio and focus on high-value generics and biosimilars are key strengths.
  • Sandoz's robust research and development capabilities, along with its efficient manufacturing network, provide significant competitive advantages.
  • Strategic focus on emerging markets and digital transformation are crucial for future growth.
  • While facing challenges such as pricing pressures and regulatory hurdles, Sandoz is well-positioned to capitalize on opportunities in the evolving pharmaceutical landscape.

FAQs

  1. Q: What is Sandoz's primary focus in the pharmaceutical industry? A: Sandoz primarily focuses on developing, manufacturing, and marketing generic pharmaceutical products and biosimilars.

  2. Q: How does Sandoz maintain its competitive edge in the market? A: Sandoz maintains its competitive edge through strong research and development capabilities, a robust global manufacturing network, strategic partnerships, and a focus on high-value generics and biosimilars.

  3. Q: What are some of the key challenges facing Sandoz in the current pharmaceutical landscape? A: Key challenges include pricing pressures, regulatory hurdles, and increased competition as patents for blockbuster drugs expire.

  4. Q: How is Sandoz addressing the growing demand for biosimilars? A: Sandoz is investing heavily in biosimilar development and was one of the first companies to receive approval for a biosimilar in the United States, positioning itself as a leader in this growing market segment.

  5. Q: What role does sustainability play in Sandoz's strategy? A: Sustainability is becoming increasingly important in Sandoz's strategy, with the company implementing various initiatives to enhance its environmental performance and appeal to environmentally conscious stakeholders.

Sources cited: [1] https://www.globaldata.com/company-profile/sandoz-inc/

Last updated: 2025-02-12

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.